Maternal serum perlecan levels in women with preeclampsia
No Thumbnail Available
Date
2020
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Objective: Perlecan is an extracellular matrix proteoglycan suggested to maintain endothelial functions. We aimed to measure maternal serum perlecan levels in different preeclampsia phenotypes. Methods: This study included 50 women with preeclampsia and 30 healthy pregnant women. Results: Serum perlecan levels were significantly higher (p = 0.016) in preeclamptic women with severe features(n = 23) than preeclampsia patients(n = 27). There were no statistically significant differences in serum perlecan levels between the early-onset preeclampsia(n = 25), late-onset preeclampsia(n = 25), and healthy pregnancies. Conclusion: Our findings suggest that preeclamptic women with severe features have higher serum perlecan levels than women with preeclampsia. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
Description
Keywords
Adult , Biomarkers , Case-Control Studies , Cross-Sectional Studies , Female , Heparan Sulfate Proteoglycans , Humans , Phenotype , Pre-Eclampsia , Pregnancy , Severity of Illness Index , perlecan , biological marker , perlecan , proteoheparan sulfate , adult , Article , clinical article , controlled study , cross-sectional study , disease severity , female , human , maternal serum , phenotype , preeclampsia , pregnant woman , protein blood level , blood , case control study , preeclampsia , pregnancy , severity of illness index